Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Di Liu
Institutions:
Gansu University of Traditional Chinese Medicine,
Gansu Provincial Hospital
Observed institutions:
Washington University in St. Louis,
Gansu University of Traditional Chinese Medicine,
Gansu Provincial Hospital
ORCID:
0000-0002-6091-1530
Observed ORCID:
0000-0002-6091-1530
OpenAlex ID:
A5065232512
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
·
Cancer Research
·
22
Corrigendum to “Malignant epithelioid angiomyolipoma of the kidney: A case report and literature review” [Asian J Sur. 49 (2025) 530–531]
2026
·
Yong-Qi Ren
, Di Liu
, et al.
·
Asian Journal of Surgery
Key steps of the modified “unroofing and base excision” technique during robot-assisted laparoscopic partial nephrectomy for localized renal tuberculosis.
2026
·
Yong Ban
, Zehua Ma
, et al.
·
ASVIDE
A modified strategy in robot-assisted laparoscopic partial nephrectomy for localized renal tuberculosis: the “unroofing and base excision” technique and clinical outcomes
2025
·
Yong Ban
, Zehua Ma
, et al.
·
Translational Andrology and Urology
Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
PDF
Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
PDF
Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
PDF
Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Data from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
PDF
Data from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
PDF
Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023
·
Yige Wu
, Siqi Chen
, et al.
Show more works
View as search
Works count:
19
Citation count:
22
H-index:
1
I10-index:
1
Year
Topic
Type